onsteroidal drugs and the antiplatelet effects of aspiri

Completed

• Conditions: ormal subjects; Normal subjects; Other -

• Registration Number: ACTRN12605000371695
• Lead Sponsor: one

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2005-09-13
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

Twelve healthy subjects were recruited from a large teaching hospital; all gave written informed consent.

Exclusion Criteria

History of platelet dysfunction or a bleeding disorder, history of peptic or duodenal ulceration or gastritits, sensitivity or allergy to aspirin or NSAID, renal impairment with serum creatinine >0.12 mmol/L, haemoglobin < 120g/l, history of coronary artery disease, peripheral vascular or cerebrovascular disease, or congestive heart failure.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Platelet function PFA-100[12 hours after an NSAID dose and 24 hours after an NSAID followed by aspirin];Urine thromboxane B2[12 hours after an NSAID dose and 24 hours after an NSAID followed by aspirin];Urine prostacyclin[12 hours after an NSAID dose and 24 hours after an NSAID followed by aspirin]

Secondary Outcome Measures

Name	Time	Method
Adverse drug reactions[Within 48 hours from taking the NSAID.]